J. Lipid Res.  Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shames, D. M.
Right arrow Articles by Havel, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shames, D. M.
Right arrow Articles by Havel, R. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol 32, 1099-1112, Copyright © 1991 by Lipid Research, Inc.


REVIEWS

De novo production of low density lipoproteins: fact or fancy

DM Shames and RJ Havel
Cardiovascular Research Institute, University of California, San Francisco 94143-0130.

Many investigators, observing an apparent dilution in the plasma specific activity (SA) of apolipoprotein B-100 (apoB) in low density lipoprotein (LDL) as compared with that in very low density lipoprotein (VLDL) after injection of radiolabeled VLDL, have formulated kinetic hypotheses incorporating the concept of de novo production of LDL to explain their data in humans and other mammals. These hypotheses, with rare exception, do not account for the kinetic heterogeneity known to exist in the apoB of human VLDL on the basis of size and in the apoB of rabbit VLDL on the basis of size and presence of apolipoprotein E. When a logical analysis of such kinetic heterogeneity of apoB in plasma VLDL is performed, it becomes clear that the apparent dilution of the SA of apoB in LDL relative to that in VLDL can be explained without the requirement for de novo production of LDL. Although this alternative hypothesis, incorporating the concept of kinetic heterogeneity of apoB in VLDL, does not exclude the process of de novo production of LDL, which so many investigators have invoked to explain their data, it does raise a question as to the existence of such a process since an alternative hypothesis can explain such data just as well. Clearly, more experimental data on the kinetic heterogeneity of human and other mammalian VLDL are needed before a reasonable choice can be made between these two hypotheses.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. Lundahl, C. Skoglund-Andersson, M. Caslake, D. Bedford, P. Stewart, A. Hamsten, C. J. Packard, and F. Karpe
Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles
Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E739 - E745.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
G. Miltiadous, V. Saougos, M. Cariolou, and M. S. Elisaf
Plasma Lipoprotein(a) Levels and LDL-Cholesterol Lowering Response to Statin Therapy in Patients with Heterozygous Familial Hypercholesterolemia
Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 353 - 355.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. M. Petit, M. Duong, E. Florentin, L. Duvillard, P. Chavanet, J. M. Brun, H. Portier, P. Gambert, and B. Verges
Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study
J. Lipid Res., September 1, 2003; 44(9): 1692 - 1697.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Pont, L. Duvillard, E. Florentin, P. Gambert, and B. Verges
Early Kinetic Abnormalities of ApoB-Containing Lipoproteins in Insulin-Resistant Women With Abdominal Obesity
Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1726 - 1732.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. S. Millar, C. Maugeais, I. V. Fuki, and D. J. Rader
Normal Production Rate of Apolipoprotein B in LDL Receptor-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 989 - 994.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Maugeais, K. Ouguerram, R. Frénais, P. Maugère, B. Charbonnel, T. Magot, and M. Krempf
Effect of Low-Density Lipoprotein Apheresis on Kinetics of Apolipoprotein B in Heterozygous Familial Hypercholesterolemia
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1679 - 1686.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
C. J. Packard, T. Demant, J. P. Stewart, D. Bedford, M. J. Caslake, G. Schwertfeger, A. Bedynek, J. Shepherd, and D. Seidel
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions
J. Lipid Res., February 1, 2000; 41(2): 305 - 318.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. G. Kraft, A. Lingenhel, F. J. Raal, M. Hohenegger, and G. Utermann
Lipoprotein(a) in Homozygous Familial Hypercholesterolemia
Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 522 - 528.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. J. Packard and J. Shepherd
Lipoprotein Heterogeneity and Apolipoprotein B Metabolism
Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3542 - 3556.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 1991 by the American Society for Biochemistry and Molecular Biology.